News articles about CTI BioPharma (NASDAQ:CTIC) have trended somewhat positive on Sunday, Accern Sentiment Analysis reports. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. CTI BioPharma earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media coverage about the biopharmaceutical company an impact score of 45.618567357303 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Shares of CTI BioPharma (NASDAQ CTIC) opened at $3.50 on Friday. CTI BioPharma has a 12 month low of $2.45 and a 12 month high of $5.28. The company has a debt-to-equity ratio of 0.26, a current ratio of 2.19 and a quick ratio of 2.17.
CTI BioPharma (NASDAQ:CTIC) last issued its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.32) by $0.04. The firm had revenue of $1.71 million for the quarter, compared to analysts’ expectations of $0.30 million. CTI BioPharma had a negative net margin of 96.91% and a negative return on equity of 209.67%. equities analysts expect that CTI BioPharma will post -1.2 EPS for the current year.
A number of research firms have recently weighed in on CTIC. ValuEngine cut shares of CTI BioPharma from a “sell” rating to a “strong sell” rating in a research note on Wednesday, October 11th. Zacks Investment Research raised shares of CTI BioPharma from a “hold” rating to a “buy” rating and set a $3.00 price target on the stock in a research note on Wednesday, December 27th.
ILLEGAL ACTIVITY WARNING: “CTI BioPharma (NASDAQ:CTIC) Receives Media Impact Score of 0.16” was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/21/cti-biopharma-ctic-getting-somewhat-favorable-media-coverage-study-shows.html.
CTI BioPharma Company Profile
CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Receive News & Ratings for CTI BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CTI BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.